Утилизация отходов биологического производства

В статье рассматривается проблема утилизации отходов, так как в год Экологии это тема стала актуальной. На каждом предприятии и в каждом доме увеличилось количество мусора и от этого страдает экологическая обстановка в каждом городе. В статье подробно узучена тема биологического производства. К биологическим отходам относятся ткани и органы, образующиеся в результате медицинской и ветеринарной оперативной практики, медико-биологических экспериментов, гибели скота, других животных и птиц, и другие отходы, получаемые при переработке пищевого и непищевого сырья животного происхождения, а также отходы биотехнологической промышленности.The article deals with the problem of waste disposal as in the year of the Environment this issue has become topical. Every enterprise and every household increased the amount of debris and suffers the environmental situation in each city. The article Azucena the theme of biological production. Biodegradable waste includes tissues and organs resulting from operational medical and veterinary practice, medical and biological experiments, loss of livestock, other animals and birds, and other waste obtained in the processing of food and non-food raw materials of animal origin and waste products of the biotechnology industry

Cascading effects of canopy mortality drive long-term changes in understorey diversity in temperate old-growth forests of Europe

Questions: We investigated the influence of protracted mortality of a dominant canopy tree (Abies alba) on long-term understorey dynamics. We ask (a) how tree regeneration and understorey species diversity and composition changed over 32 years; and (b) whether the observed changes were mainly driven by mortality of A. alba. Location: Three old-growth forest reserves dominated by A. alba and Fagus sylvatica in the Dinaric Mountains of Slovenia. Method: Tree layer and understorey regeneration and herbs were surveyed in 147 plots across the three forest reserves in 1983 and 2015. Soils were also sampled in 2015. The study period coincides with a protracted period of increased A. alba mortality in the canopy layer associated with anthropogenic emissions. Results: Between 1983 and 2015, the decline in canopy layer A. alba caused a recruitment pulse of F. sylvatica regeneration to the subcanopy tree layer across the three reserves. These changes were accompanied by a significant decline in plot level herb species richness. A model-based analysis of beta-diversity revealed significant community convergence during the study period, mainly caused by the loss of rare species. Ellenberg values indicate that these changes were mainly driven by loss of understorey light, while an increase in soil pH may have played a role also. Conclusions: This observational study suggests that the long-term decline of A. alba resulted in a cascade of processes - widespread F. sylvatica recruitment that impeded penetration of light to the forest floor, and possibly a change in soil conditions due to the decline of coniferous litter. These changes caused a significant loss of herb diversity and homogenization of the understorey community across the three sites. This study sheds light on the potential cascading consequences triggered by episodes of increased tree mortality resulting from global-change-type drivers

Совершенствование системы найма и адаптации персонала на предприятии

Объектом исследования является: торговая компания ООО "Симост". В рамках магистерской работы проводились исследования теоретических и методологических основ найма и адаптации персонала в компании. Был проведен анализ состава, структуры и движения персонала, изучена система найма и адаптации в компании "Симост". В результате исследования автором была предложена система мероприятий по совершенствованию процесса найма и адаптации персонала в компании "Симост".The object of the study is: the trading company "Simost". In the master's thesis, research was carried out on the theoretical and methodological foundations of hiring and adaptation of personnel in the company. An analysis was made of the composition, structure and movement of personnel, the hiring and adaptation system in the company "Simost" was studied. As a result of the research, the author proposed a system of measures to improve the process of recruitment and adaptation of personnel in the company "Simost"

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

PurposeHigh-dose pegylated interferon α-2b (peginterferon α-2b) significantly decreased disease recurrence in patients with resected stage III melanoma in a clinical study. We investigated the pharmacokinetics (PK) and safety of high-dose peginterferon α-2b in patients with high-risk melanoma.MethodsFor PK analysis, 32 patients received peginterferon α-2b 6 μg/(kg week) subcutaneously for 8 weeks (induction) then 3 μg/(kg week) for 4 weeks (maintenance). PK profiles were determined at weeks 1, 8, and 12. Exposure-response relationships between peginterferon α-2b and absolute neutrophil count (ANC) and alanine aminotransferase (ALT) level were also studied.ResultsPeginterferon α-2b was well-absorbed following SC administration, with a median T (max) of 24 h. Mean half-life estimates ranged from 43 to 51 h. The accumulation factor was 1.69 after induction therapy. PK parameters showed moderate interpatient variability. PK profiles were described by a one-compartmental model with first-order absorption and first-order elimination. Toxicity was profiled and was acceptable; observed side effects were similar to those previously described. Dose reduction produced proportional decreases in exposure and predictable effects on ANC in an Imax model; however, a PK/pharmacodynamic (PK/PD) relationship between peginterferon α-2b and ALT could not be established with high precision.ConclusionsPeginterferon α-2b was well-absorbed and sustained exposure to peginterferon α-2b was achieved with the doses tested. These data confirm and extend previous PK observations of peginterferon α-2b in melanoma and solid tumors. Our PK/PD model of exposure and ANC effect provides useful information for prediction of peginterferon α-2b-related hematologic toxicity

Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity

All-trans-retinoic acid is a potent inhibitor of cell proliferation and inducer of differentiation. However, the clinical use of all-trans-retinoic acid in the treatment of cancer is significantly hampered by its toxicity and the prompt emergence of resistance, believed to be caused by increased all-trans-retinoic acid metabolism. Inhibitors of all-trans-retinoic acid metabolism may therefore prove valuable in the treatment of cancer. In this study, we characterize R116010 as a new anticancer drug that is a potent inhibitor of all-trans-retinoic acid metabolism. In vitro, R116010 potently inhibits all-trans-retinoic acid metabolism in intact T47D cells with an IC50-value of 8.7 nM. In addition, R116010 is a selective inhibitor as indicated by its inhibition profile for several other cytochrome P450-mediated reactions. In T47D cell proliferation assays, R116010 by itself has no effect on cell proliferation. However, in combination with all-trans-retinoic acid, R116010 enhances the all-trans-retinoic acid-mediated antiproliferative activity in a concentration-dependent manner. In vivo, the growth of murine oestrogen-independent TA3-Ha mammary tumours is significantly inhibited by R116010 at doses as low as 0.16 mg kg−1. In conclusion, R116010 is a highly potent and selective inhibitor of all-trans-retinoic acid metabolism, which is able to enhance the biological activity of all-trans-retinoic acid, thereby exhibiting antitumour activity. R116010 represents a novel and promising anticancer drug with an unique mechanism of action

Arthropod distribution in a tropical rainforest: tackling a four dimensional puzzle

Quantifying the spatio-temporal distribution of arthropods in tropical rainforests represents a first step towards scrutinizing the global distribution of biodiversity on Earth. To date most studies have focused on narrow taxonomic groups or lack a design that allows partitioning of the components of diversity. Here, we consider an exceptionally large dataset (113,952 individuals representing 5,858 species), obtained from the San Lorenzo forest in Panama, where the phylogenetic breadth of arthropod taxa was surveyed using 14 protocols targeting the soil, litter, understory, lower and upper canopy habitats, replicated across seasons in 2003 and 2004. This dataset is used to explore the relative influence of horizontal, vertical and seasonal drivers of arthropod distribution in this forest. We considered arthropod abundance, observed and estimated species richness, additive decomposition of species richness, multiplicative partitioning of species diversity, variation in species composition, species turnover and guild structure as components of diversity. At the scale of our study (2km of distance, 40m in height and 400 days), the effects related to the vertical and seasonal dimensions were most important. Most adult arthropods were collected from the soil/litter or the upper canopy and species richness was highest in the canopy. We compared the distribution of arthropods and trees within our study system. Effects related to the seasonal dimension were stronger for arthropods than for trees. We conclude that: (1) models of beta diversity developed for tropical trees are unlikely to be applicable to tropical arthropods; (2) it is imperative that estimates of global biodiversity derived from mass collecting of arthropods in tropical rainforests embrace the strong vertical and seasonal partitioning observed here; and (3) given the high species turnover observed between seasons, global climate change may have severe consequences for rainforest arthropods1012CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQSolVin-Solvay SA; Smithsonian Institution; Smithsonian Tropical Research Institute; United Nations Environment Programme; Smithsonian Institution; Smithsonian National Museum of Natural History; European Science Foundation (ESF); Global Canopy Programme; Czech Science foundation GACR grant; European Social Fund (ESF); Ministry of Education, Youth & Sports - Czech Republic; French National Research Agency (ANR); Research Council of Norway; Grant Agency of the Czech Republi

Influence of surgical approach on component positioning in primary total hip arthroplasty

Background: Minimal invasive surgery (MIS) has gained growing popularity in total hip arthroplasty (THA) but concerns exist regarding component malpositioning. The aim of the present study was to evaluate femoral and acetabular component positioning in primary cementless THA comparing a lateral to a MIS anterolateral approach. Methods: We evaluated 6 week postoperative radiographs of 52 hips with a minimal invasive anterolateral approach compared to 54 hips with a standard lateral approach. All hips had received the same type of implant for primary cementless unilateral THA and had a healthy hip contralaterally. Results: Hip offset was equally restored comparing both approaches. No influence of the approach was observed with regard to reconstruction of acetabular offset, femoral offset, vertical placement of the center of rotation, stem alignment and leg length discrepancy. However, with the MIS approach, a significantly higher percentage of cups (38.5 %) was malpositioned compared to the standard approach (16.7 %) (p = 0.022). Conclusions: The MIS anterolateral approach allows for comparable reconstruction of stem position, offset and center of rotation compared to the lateral approach. However, surgeons must be aware of a higher risk of cup malpositioning for inclination and anteversion using the MIS anterolateral approach

Land-use effects on local biodiversity in tropical forests vary between continents

The file attached is the Published/publisher’s pdf version of the article

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)